Fielded among 104 U.S. rheumatologists in January 2026, the study indicates that nearly half are already aware of the upcoming FDA decision. Unaided, Sotyktu is the most frequently cited pipeline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results